Dynavax Technologies Corporation

NasdaqGS:DVAX 주식 보고서

시가총액: US$1.4b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Dynavax Technologies 미래 성장

Future 기준 확인 4/6

Dynavax Technologies은 연간 수입과 매출이 각각 42.9%와 18.9% 증가할 것으로 예상되고 EPS는 연간 40.5%만큼 증가할 것으로 예상됩니다.

주요 정보

42.9%

수익 성장률

40.5%

EPS 성장률

Biotechs 수익 성장24.2%
매출 성장률18.9%
향후 자기자본 수익률n/a
애널리스트 커버리지

Low

마지막 업데이트05 Jun 2024

최근 미래 성장 업데이트

Recent updates

Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S

May 22
Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S

Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain

May 10

Dynavax: Holding Firm Despite Its Missing Cash Cow

Mar 23

Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

Mar 06
Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry

Jan 31
Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry

These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely

Aug 02
These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely

Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet

Jun 02
Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet

We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease

May 03
We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease

Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly

Jan 16
Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly

Clover, Dynavax COVID-19 vaccine gets EU GMP certificate

Sep 20

Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

Sep 12
Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

The Alphavaxers: Dynavax And Novavax, 2 Quarters On

Aug 22

Dynavax up 8% after raising full-year guidance for key adjuvant product, Q2 beats

Aug 04

Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?

Jun 03
Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?

Dynavax: Evolving Endemic Situation Adds To Its Risk

May 23

Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest

May 12
Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest

Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt

May 10
Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt

Dynavax Technologies: Full Speed Ahead

Mar 01

Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly

Jan 28
Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly

Dynavax: A Coronavirus Growth Story

Jan 17

Is Dynavax Technologies Corporation (NASDAQ:DVAX) Expensive For A Reason? A Look At Its Intrinsic Value

Nov 18
Is Dynavax Technologies Corporation (NASDAQ:DVAX) Expensive For A Reason? A Look At Its Intrinsic Value

The Momentum Investor: Spotlight On Dynavax Technologies

Oct 25

Dynavax And TLR Biology: Long-Delayed But Outstanding Success

Oct 16

These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Reasonably Well

Oct 02
These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Reasonably Well

Upgrade: Analysts Just Made A Meaningful Increase To Their Dynavax Technologies Corporation (NASDAQ:DVAX) Forecasts

Aug 10
Upgrade: Analysts Just Made A Meaningful Increase To Their Dynavax Technologies Corporation (NASDAQ:DVAX) Forecasts

Dynavax: Earnings This Year Ought To Surprise To The Upside

Aug 01

수익 및 매출 성장 예측

NasdaqGS:DVAX - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/20264076890994
12/31/20253494755705
12/31/2024285192255
3/31/202423695356N/A
12/31/2023232-696101N/A
9/30/202336161118122N/A
6/30/2023459111147152N/A
3/31/2023656236134141N/A
12/31/20227232935663N/A
9/30/2022733320140148N/A
6/30/2022674228142153N/A
3/31/2022470104238247N/A
12/31/202143972326336N/A
9/30/2021258-39192199N/A
6/30/2021163-6101105N/A
3/31/2021113-62-31-27N/A
12/31/202040-75-103-92N/A
9/30/202038-97-112-100N/A
6/30/202035-138-115-94N/A
3/31/202040-129-136-108N/A
12/31/201935-156-151-121N/A
9/30/201930-159-161-132N/A
6/30/201921-163-166-144N/A
3/31/201914-160-157-141N/A
12/31/20188-159-146-131N/A
9/30/20183-146-130-115N/A
6/30/20181-128-110-99N/A
3/31/20180-109-93-82N/A
12/31/20170-95N/A-78N/A
9/30/20178-89N/A-86N/A
6/30/20178-102N/A-97N/A
3/31/201710-111N/A-105N/A
12/31/201611-112N/A-107N/A
9/30/20164-118N/A-103N/A
6/30/20165-113N/A-97N/A
3/31/20164-108N/A-96N/A
12/31/20154-107N/A-93N/A
9/30/20156-102N/A-88N/A
6/30/20157-102N/A-88N/A
3/31/20158-103N/A-87N/A
12/31/201411-91N/A-74N/A
9/30/201412-90N/A-69N/A
6/30/201412-76N/A-58N/A
3/31/201413-68N/A-51N/A
12/31/201311-75N/A-59N/A
9/30/201310-74N/A-54N/A
6/30/201310-76N/A-55N/A

애널리스트 미래 성장 예측

수입 대 저축률: DVAX 의 연간 예상 수익 증가율( 42.9% )이 saving rate( 2.4% 보다 높습니다. ).

수익 vs 시장: DVAX 의 연간 수익( 42.9% ) US 시장( 14.9% 보다 빠르게 성장할 것으로 예상됩니다. 14.9% 연간).

고성장 수익: DVAX 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: DVAX 의 수익(연간 18.9% ) US 시장( 8.7% 보다 빠르게 성장할 것으로 예상됩니다. 8.7% 연간).

고성장 수익: DVAX 의 수익(연간 18.9% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: DVAX 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.


성장 기업 발견